New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment
Achieving glycemic control and sustaining functional pancreatic β-cell activity remains an unmet medical need in the treatment of type 2 diabetes mellitus (T2DM). Glucokinase activators (GKAs) constitute a class of anti-diabetic drugs designed to regulate blood sugar levels and enhance β-cell functi...
Main Authors: | Dania Haddad, Vanessa Sybil Dsouza, Fahd Al-Mulla, Ashraf Al Madhoun |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/25/1/571 |
Similar Items
-
Evaluation of efficacy and safety of glucokinase activators—a systematic review and meta-analysis
by: Wenjia Yang, et al.
Published: (2023-05-01) -
Decreased expression of hepatic glucokinase in type 2 diabetes
by: Rebecca A. Haeusler, et al.
Published: (2015-03-01) -
Quinazolin-4-one derivatives lacking toxicity-producing attributes as glucokinase activators: design, synthesis, molecular docking, and in-silico ADMET prediction
by: Saurabh C. Khadse, et al.
Published: (2019-12-01) -
Conformational transition pathway of R308K mutant glucokinase in the presence of the glucokinase activator YNKGKA4
by: Nanda Kumar Yellapu, et al.
Published: (2018-08-01) -
Molecular docking assessment of pyridone derivatives as glucokinase activators
by: Y. Nanda Kumar, et al.
Published: (2012-10-01)